Moderna Competitors and Similar CompaniesClear all
Moderna's competitors and similar companies include Regulus Therapeutics, Alnylam and Sarepta Therapeutics.
 Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. |  Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | |
Founding Date | Founding Date 2010 | Founding Date 2007 | Founding Date 2002 | Founding Date 1980 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations San Diego, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | ||
Employees | Employees 5,60044% increase | Employees 2462% decrease | Employees 1,32324% increase | Employees 1,31413% increase |
Valuation ($) | Valuation ($) 21.2 b | Valuation ($) 105.4 m | Valuation ($) 36.5 b | Valuation ($) 12.4 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $6.8b (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $1.2b (FY, 2023) |
Cost of goods | Cost of goods $4.7b (FY, 2023) | Cost of goods N/A | Cost of goods $268.2m (FY, 2023) | Cost of goods $150.3m (FY, 2023) |
Gross profit | Gross profit $2.2b (FY, 2023) | Gross profit N/A | Gross profit $1.6b (FY, 2023) | Gross profit $1.1b (FY, 2023) |
Net income | Net income ($4.7b) (FY, 2023) | Net income ($30m) (FY, 2023) | Net income ($440.2m) (FY, 2023) | Net income ($536m) (FY, 2023) |
Operating ⚠ | ||||
Patents Issued | Patents Issued 270 (FY, 2020) | Patents Issued 300 (FY, 2016) | Patents Issued N/A | Patents Issued N/A |
Funding | ||||
Total funding raised | Total funding raised $ 1.8b | Total funding raised $ 10m | Total funding raised $ 1.5b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Regulus Therapeutics
HQ
San Diego, US
Employees
24
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companySarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
View company